Table 4.

Recommended dosing of DPP-4 inhibitors in patients with T2DM and CKD.

	Severity of CKD
	No or Mild CKD (CrCl ≥50 mL/min)	Moderate (CrCl ≥30 to <50 mL/min)	Severe/ESRD (CrCl <30 mL/min)
Alogliptin [22]	25 mg qd*	12.5 mg qd†	6.25 mg qd
Linagliptin [19]	5 mg qd	5 mg qd	5 mg qd
Saxagliptin [21]	5 mg qd‡	2.5 mg qd	2.5 mg qd
Sitagliptin [20]	100 mg qd	50 mg qd	25 mg qd

*CrCl ≥60 mL/min.

^†For CrCl ≥30 to <60 mL/min.‡For CrCl >50 mL/min.

CKD, chronic kidney disease; CrCl, creatinine clearance; DPP-4, dipeptidyl peptidase-4 inhibitors; ESRD, end-stage renal disease; qd, once daily; T2DM, type 2 diabetes mellitus.